This analysis uses 2023 Medicare claims for traditional Medicare, Medicare Advantage encounter data, and Part D prescription drug event data to estimate the total number of Medicare beneficiaries with obesity or overweight, the number of Part D enrollees who met the Bridge eligibility criteria in 2023, and those who met the Bridge clinical criteria but who also had diagnoses recorded in claims or encounter data that would qualify for Part D coverage of GLP-1s (type 2 diabetes, OSA, or MASH) or who had a GLP-1 Part D-covered prescription during the year, either of which would make them ineligible for Bridge (see Methods)
What to track weekly At minimum, track these variables every week throughout your dose schedule
The approval marked a milestone in OSA treatment: the first pharmacologic option shown to address contributing metabolic pathways of the condition rather than airway obstruction alone
Give it at least three weeks before deciding something is wrong
How does Retatrutide compare to Ozempic or Wegovy
This ongoing support helps patients build better nutrition, sleep, and exercise habits, making it easier to turn short-term results into long-term success
